Skip to main content
Apeloa Pharmaceutical Co.,Ltd. logo

Apeloa Pharmaceutical Co.,Ltd. — Investor Relations & Filings

Ticker · 000739 ISIN · CNE000000Q45 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,843 across all filing types
Latest filing 2014-07-11 Capital/Financing Update
Country CN China
Listing Shenzhen Stock Exchange 000739

About Apeloa Pharmaceutical Co.,Ltd.

https://www.apeloa.com

Apeloa Pharmaceutical Co., Ltd. focuses on the research, development, manufacturing, and distribution of active pharmaceutical ingredients (APIs), intermediates, and finished dosage forms. The company operates three core business pillars: API production, Contract Development and Manufacturing Organization (CDMO) services, and finished drug products. Its therapeutic focus includes cardiovascular, anti-infective, anti-viral, and oncology treatments. Apeloa utilizes an integrated supply chain to deliver chemical and biological solutions to a global client base. The organization maintains compliance with international quality standards, including certifications from the FDA, EMA, and PMDA. Its CDMO services encompass the full product lifecycle, from process chemistry and analytical development to large-scale commercial manufacturing, supported by specialized technology platforms such as continuous flow chemistry and enzymatic synthesis.

Recent filings

Filing Released Lang Actions
关于非公开发行股票获得中国证监会发审会审核通过的公告
Capital/Financing Update Classification · 95% confidence The document is a short announcement regarding the approval of a non-public stock issuance by the China Securities Regulatory Commission. It mentions the company's application for non-public stock issuance has been approved and that a further announcement will be made upon receipt of the official approval document. The document is brief (345 characters) and does not contain financial statements or detailed financial data. It is an update on financing activity, specifically about capital raising through stock issuance. Therefore, it fits the category of Capital/Financing Update (CAP).
2014-07-11 Chinese
关于公司注射用索法地尔获得Ⅰ期临床试验批件的公告
Regulatory Filings Classification · 95% confidence The document is a company announcement regarding the receipt of a clinical trial approval from the National Medical Products Administration for a drug under development. It includes details about the drug, ownership, and clinical trial plans. There is no financial data, no mention of financial results, no regulatory filings about financial performance, and no mention of shareholder votes or management changes. The document is an official announcement about a regulatory approval related to drug development, which does not fit into financial report categories like Annual Report, Interim Report, Earnings Release, or Capital Update. It is a regulatory announcement about clinical trial approval, which is best classified under Regulatory Filings (RNS) as a general regulatory announcement that does not fit other categories.
2014-07-10 Chinese
2014年半年度业绩预告
Earnings Release Classification · 95% confidence The document is titled '2014 年半年度业绩预告' which translates to '2014 Half-Year Performance Forecast'. It provides estimated financial results for the period January 1, 2014 to June 30, 2014, including expected net profit and earnings per share. It explicitly states that the forecast has not been audited and that actual financial data will be in the 2014 half-year report. The document is a performance forecast, not the actual interim report containing audited or substantive financial data. Therefore, it is an Earnings Release (ER) type document, as it announces key financial highlights for a quarterly/periodical period but does not contain full financial statements or detailed analysis. H1 2014
2014-07-10 Chinese
风险提示公告
Capital/Financing Update Classification · 95% confidence The document is a public announcement by 普洛药业股份有限公司 regarding the risks associated with a non-public issuance of shares in 2014. It details the number of shares to be issued, the intended use of the raised funds, potential dilution of immediate returns, and measures the company plans to take to mitigate these risks. The document includes risk warnings, management strategies, and references to board and shareholder meetings approving the issuance. It does not contain financial statements or detailed financial performance data, nor is it a transcript, audit report, or regulatory certification. The focus is on informing investors about the capital raising event and associated risks, which aligns with a Capital/Financing Update. The document length is 4022 characters, which is sufficient for a detailed announcement but not a full annual or interim report. Therefore, the most appropriate classification is Capital/Financing Update (CAP).
2014-06-11 Chinese
关于实施2013年度分红派息、转增股本后调整非公开发行股票发行价格和发行数量的公告
Capital/Financing Update Classification · 100% confidence The document is an announcement regarding the adjustment of the issuance price and quantity of a non-public stock offering following a dividend distribution and capital increase. It details the revised issuance price per share, the adjusted number of shares to be issued, and the subscription details for the investors. The content focuses on changes to a capital raising event rather than presenting financial statements or a full report. The document length is short (1387 characters) and it is clearly an update on financing terms. Therefore, it fits best under the category of Capital/Financing Update (CAP).
2014-06-11 Chinese
关于本次募集资金项目效益与前次重大资产重组承诺效益区分核算的提示性公告
Capital/Financing Update Classification · 90% confidence The document is a public announcement by 普洛药业股份有限公司 regarding the effectiveness of funds raised in a recent financing project and the distinction of these benefits from those promised in a previous major asset restructuring. It discusses details about the previous asset restructuring, profit commitments, and how the new funds will be accounted for separately to protect interests. The document includes formulas for calculating the impact of the new funds on previous commitments and mentions that further detailed reports and audit opinions will be provided later. The document length is 3158 characters, which is relatively short and primarily serves as an announcement or explanatory notice rather than a full financial report. It does not contain comprehensive financial statements or detailed financial analysis but rather explains the accounting treatment and commitments related to fundraising and asset restructuring. Therefore, it fits best as a Capital/Financing Update (CAP) because it deals with fundraising, use of proceeds, and related financial commitments and clarifications.
2014-06-11 Chinese

Browse filings by year

27 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.